CytokineticsCYTK
CYTK
About: Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Employees: 498
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
302% more call options, than puts
Call options by funds: $184M | Put options by funds: $45.7M
29% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 108
24% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 45
2.8% more ownership
Funds ownership: 111.27% [Q4 2024] → 114.07% (+2.8%) [Q1 2025]
2% more funds holding
Funds holding: 343 [Q4 2024] → 351 (+8) [Q1 2025]
11% less capital invested
Capital invested by funds: $6.18B [Q4 2024] → $5.53B (-$655M) [Q1 2025]
20% less funds holding in top 10
Funds holding in top 10: 15 [Q4 2024] → 12 (-3) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$41
14%
upside
Avg. target
$66
84%
upside
High target
$84
134%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
JP Morgan Tessa Romero | 48%upside $53 | Overweight Maintained | 9 Jun 2025 |
Mizuho Salim Syed | 134%upside $84 | Outperform Maintained | 29 May 2025 |
Needham Serge Belanger | 101%upside $72 | Buy Reiterated | 14 May 2025 |
Barclays Gena Wang | 48%upside $53 | Overweight Maintained | 8 May 2025 |
RBC Capital Leonid Timashev | 123%upside $80 | Outperform Maintained | 7 May 2025 |
Financial journalist opinion
Based on 4 articles about CYTK published over the past 30 days
Positive
Seeking Alpha
4 days ago
Cytokinetics Merits A Speculative Buy Rating
Cytokinetics continues to near unaminous positive analyst sentiment, with most price targets well above current levels, reflecting strong growth expectations. The company's NDA around its lead drug candidate was delayed by three months recently. However, Cytokinetics maintains a robust cash position of $1.1 billion, supporting ongoing operations and R&D. If all goes according to schedule, Cytokinetics should receive the first of many FDA approvals late this year and has several potential catalysts on the horizon.
Neutral
GlobeNewsWire
5 days ago
Cytokinetics to Announce Second Quarter Results On August 7, 2025
SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.
Neutral
GlobeNewsWire
1 week ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.
Neutral
GlobeNewsWire
2 weeks ago
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy
Neutral
GlobeNewsWire
1 month ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,583 shares of common stock and 56,334 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in May and June, 2025, as a material inducement to their employment.
Neutral
Accesswire
1 month ago
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CYTK
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Neutral
Accesswire
1 month ago
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Neutral
Accesswire
1 month ago
Lost Money on Cytokinetics, Incorporated(CYTK)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Neutral
Accesswire
1 month ago
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CYTK
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Neutral
Accesswire
1 month ago
Shareholders that Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud Investigation - CYTK
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
Charts implemented using Lightweight Charts™